Shopping Cart 0
Cart Subtotal
USD 0

Halozyme Therapeutics Inc (HALO) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Halozyme Therapeutics Inc (HALO)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes to provide innovative products for cancer, dermatology, diabetes and drug delivery markets. The company's marketed product, Hylenex is an agent for drug and fluid infusion. Its pipeline products include analog insulin PH20, for the treatment of diabetes; PEGPH20, for the treatment of pancreatic cancer; and HTI-501, for the treatment of scarring, among others. Its products are based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes affecting the extracellular matrix. Its Enhanze technology is a novel drug delivery platform proposed to enhance the absorption and dispersion of biologics. The company has partnerships with Pfizer, Roche, Baxter and Intrexon for the development and commercialization of drugs. Halozyme is headquartered in San Diego, California, the US.

Halozyme Therapeutics Inc Key Recent Developments

May 10,2018: Halozyme Reports First Quarter 2018 Results

Feb 20,2018: Halozyme Reports Fourth Quarter And Full-Year 2017 Results

Jan 09,2018: Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018

Nov 07,2017: Halozyme Reports Third Quarter 2017 Results

Sep 14,2017: Halozyme Increases 2017 Financial Guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Halozyme Therapeutics Inc-Key Facts 6

Halozyme Therapeutics Inc-Key Employees 7

Halozyme Therapeutics Inc-Key Employee Biographies 8

Halozyme Therapeutics Inc-Major Products and Services 9

Halozyme Therapeutics Inc-History 10

Halozyme Therapeutics Inc-Company Statement 13

Halozyme Therapeutics Inc-Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2-Company Analysis 16

Company Overview 16

Halozyme Therapeutics Inc-Business Description 17

Geographical Segment: All other foreign 17

Performance 17

Geographical Segment: Switzerland 17

Performance 17

Geographical Segment: The US 17

Performance 17

R&D Overview 18

Halozyme Therapeutics Inc-Corporate Strategy 19

Halozyme Therapeutics Inc-SWOT Analysis 20

SWOT Analysis-Overview 20

Halozyme Therapeutics Inc-Strengths 20

Halozyme Therapeutics Inc-Weaknesses 21

Halozyme Therapeutics Inc-Opportunities 22

Halozyme Therapeutics Inc-Threats 23

Halozyme Therapeutics Inc-Key Competitors 24

Section 3-Company Financial Ratios 25

Financial Ratios-Capital Market Ratios 25

Financial Ratios-Annual Ratios 26

Performance Chart 28

Financial Performance 28

Financial Ratios-Interim Ratios 29

Financial Ratios-Ratio Charts 30

Section 4-Company's Lifesciences Financial Deals and Alliances 31

Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32

Halozyme Therapeutics Inc, Recent Deals Summary 33

Section 5-Company's Recent Developments 34

May 10, 2018: Halozyme Reports First Quarter 2018 Results 34

Feb 20, 2018: Halozyme Reports Fourth Quarter And Full-Year 2017 Results 35

Jan 09, 2018: Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018 36

Nov 07, 2017: Halozyme Reports Third Quarter 2017 Results 37

Sep 14, 2017: Halozyme Increases 2017 Financial Guidance 39

Aug 08, 2017: Halozyme Reports Second Quarter 2017 Results 40

May 09, 2017: Halozyme Reports First Quarter 2017 Financial Results 41

Feb 28, 2017: Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results 42

Section 6-Appendix 44

Methodology 44

Ratio Definitions 44

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

Halozyme Therapeutics Inc, Performance Chart (2013-2017) 28

Halozyme Therapeutics Inc, Ratio Charts 30

Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32


List Of Table

List of Tables

Halozyme Therapeutics Inc, Key Facts 6

Halozyme Therapeutics Inc, Key Employees 7

Halozyme Therapeutics Inc, Key Employee Biographies 8

Halozyme Therapeutics Inc, Major Products and Services 9

Halozyme Therapeutics Inc, History 10

Halozyme Therapeutics Inc, Subsidiaries 15

Halozyme Therapeutics Inc, Key Competitors 24

Halozyme Therapeutics Inc, Ratios based on current share price 25

Halozyme Therapeutics Inc, Annual Ratios 26

Halozyme Therapeutics Inc, Annual Ratios (Cont...1) 27

Halozyme Therapeutics Inc, Interim Ratios 29

Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32

Halozyme Therapeutics Inc, Recent Deals Summary 33

Currency Codes 44

Capital Market Ratios 44

Equity Ratios 45

Profitability Ratios 45

Cost Ratios 46

Liquidity Ratios 46

Leverage Ratios 47

Efficiency Ratios 47

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Halozyme Therapeutics Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Valeant Pharmaceuticals International Inc

Novavax Inc

MilliporeSigma

CTI BioPharma Corp

Celltrion Inc

Avanir Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc